Answers are grounded in this paper and cite their sources.
This review evaluates clinical effectiveness and cost-effectiveness of blinatumomab in Canada, suggesting implications for reimbursement decisions.
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses blinatumomab (Blincyto), 28 mcg/day for patients weighing 45 kg and more and 15 mcg/m2 per day for patients weighing less than 45 kg (up to a maximum of 28 mcg/day), lyophilized powder for solution, IV infusion by infusion pump. Indication: For the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: